MSGene

MSGene - Gene overview of all published MS-association studies for APOE

Gene:

APOE (AD2; LDLCQ5; LPG; MGC1571)

View on ALSGene View on AlzGene View on PDGene View on SZGene

Protein:

apolipoprotein E (apolipoprotein E3)

Chromosome:

19 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 24 July 2010

1. Case-Control Studies (by ethnic group)
				MS Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result
Caucasian
Ballerini, 2000	Italy	CL	2 (detail)	66 (70%)	P	27.8 + 6.1 (-)	43 + 10 (-)	67 (52%)	40 + 5 (-)	Positive
Barcellos, 1997	USA	CL	1 (detail)	120 (-)	O/M	-	-	107 (-)	-	Trend
Carlin, 2000	UK (Scotland)	CL	2 (detail)	71 (58%)	O/M	-	58.5 (31-89)	41 (-)	50.8 (18-82)	Negative
Chapman, 2001	Israel	CL	1 (detail)	205 (64%)	P	34.4 + 0.9 (-)	-	154 (-)	-	Positive
Fazekas, 2001	Austria	CL	2 (detail)	374 (70%)	P	-	40 + 10.8 (-)	389 (50%)	60.1 + 6.1 (50-70)	Positive
Ferri, 1999	Italy	CL	2 (detail)	161 (67%)	U	-	40.9 + 11.3 (-)	153 (32%)	56.2 + 5.3 (-)	Negative
Gaillard, 1998	France	CL	2 (detail)	70 (76%)	P	-	-	99 (47%)	-	Negative
Hogh, 2000	Denmark	CL,PO	2 (detail)	240 (65%)	U	30 + 9.3 (-)	41.7 + 10 (19-80)	361 (51%)	50 + 0 (50-50)	n.a.
Koutsis, 2007	Greece	CL	2 (detail)	212 (64%)	MD2	30.1 + 9.9 (10-64)	38.7 + 10.4 (16-69)	216 (32%)	35.6 + 11.5 (-)	Negative
Lucotte, 2000	France	CL	2 (detail)	100 (57%)	P	30 (16-59)	-	248 (-)	-	Positive
Pirttila, 2000	Finland	CL	2 (detail)	105 (68%)	P	34 + 10 (-)	39 + 10 (-)	1919 (-)	-	Negative
Ramsaransing, 2005	Netherlands	CL	2 (detail)	82 (67%)	P	32.3 + 8.5 (-)	49.9 + 9.4 (-)	29 (52%)	44 + 10.1 (-)	Negative
Rosche, 2004	Germany	CL	2 (detail)	267 (71%)	O/M	-	41 + 12.4 (-)	227 (57%)	41.5 + 16.3 (-)	Negative
Rubinsztein, 1994	UK (England)	CL	2 (detail)	36 (64%)	P	-	58 (-)	91 (37%)	56 (-)	Negative
Santos, 2004	Portugal	CL	2 (detail)	243 (70%)	P	29 + 9.7 (-)	38.3 + 10.8 (-)	192 (-)	-	Positive
Savettieri, 2003	Italy	CL,PO	2 (detail)	428 (62%)	P	27.3 + 8.3 (-)	38 + 9.3 (-)	107 (48%)	-	Negative
Weatherby, 2000a	UK (England)	CL	2 (detail)	370 (75%)	P	31 + 9.1 (-)	43.8 + 11.2 (-)	159 (60%)	45.6 + 12.8 (-)	Negative
Zakrzewska-Pniewska, 2004	Poland	CL	2 (detail)	117 (63%)	MD1	31.2 (-)	44.1 + 11.8 (18-73)	100 (59%)	74.2 + 5.6 (62-95)	Negative
Zwemmer, 2004	Netherlands	CL	2 (detail)	408 (61%)	P	32 + 10 (-)	46 + 11 (-)	144 (50%)	41 (-)	Negative
Asian
Barcellos, 1997	China	CL	1 (detail)	32 (-)	O/M	-	-	32 (-)	-	Positive
Niino, 2003	Japan	CL	2 (detail)	135 (72%)	MD1	26.8 + 9.3 (-)	34.9 + 10.7 (-)	134 (68%)	32.8 + 8.9 (20-58)	Negative
Other/Mixed
Al-Shammri, 2005	Kuwait	CL	2 (detail)	39 (56%)	P	-	-	106 (-)	-	Trend

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine MS diagnosis -> "P" (Poser criteria, 1983), "MD1" (McDonald criteria, 2001), "MD2" (revised McDonald criteria, 2005), "MD1&2" (McDonald criteria, 2001 and 2005), "O/M" (other/mixed), "U" (Unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.

Print this page

Email this page

MSDF RSS

Text size

Share & Bookmark

MSGene Recent Updates

MSGene Top Results